Gilead upgraded to Buy by Needham as Yeztugo gains physician favor, with sales forecast to reach $6.4 billion by 2035, ...

Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Needham upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold on Friday, citing a physical survey to suggest that the ...

Yeztugo, a twice yearly injection, offers a promising advancement in HIV prevention, but high costs and insurance uncertainties may limit its accessibility.

Northwell Health is now offering a new injection that promises to reduce the risk of HIV and AIDS. Doctors say it will combat ...

The FDA has approved the first 100% effective HIV prevention drug, lenacapavir, set to be distributed globally and potentially save millions of lives.

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion under accelerated ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Gilead researchers and collaborators will present new Phase 3 ...